Doctor D Puts Big Pharma’s American Markup on Hospice as Nine Drugmakers Volunteer at Tariff-Point
“Look how they massacred my boy margins.” -Big Pharma executives, probably
Doctor Donnie has announced that nine more drugmakers have agreed to lower their prices in the United States.
And by “agreed,” I mean Trump announced the other 10% of the pharmaceutical industry is also coming because they “have no choice.”
Ah yes, the purest form of corporate consent: Sign here before Donnie asks RFK Jr. what’s inside your warehouse.
The latest companies entering Trump’s drug-pricing Thunderdome are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio Pharma, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB.
Under the agreements, all nine drugmakers will provide every state Medicaid program with prices matching those paid in other developed countries.
I’m no healthcare economist, but “the same pill shouldn’t cost four times more because it crossed the Atlantic” feels like something we could’ve figured out before 2026.
According to a 2024 RAND study, U.S. prescription drug prices averaged nearly three times what other countries paid. Think that’s bad? Branded medicines were more than four times as expensive.
Trump has made unveiling the Epstein files closing that gap one of the centerpieces of his healthcare agenda. He signed an executive order in May 2025 directing his administration to tie American drug prices to the lowest prices offered across other developed nations.
Since then, the White House has been calling drugmakers into the principal’s office one batch at a time.
The administration started with Pfizer, then worked its way through companies including Eli Lilly, Novo Nordisk, Merck, AbbVie, Johnson & Johnson, Bristol Myers Squibb, Amgen, Gilead Sciences, and Regeneron.
Monday’s announcement brings the total to 26 drugmakers, covering 89% of the branded-drug market, according to the White House.
The other 11% is presumably hiding beneath a lab table, whispering, “Maybe he’ll forget about us.”
(read in Morgan Freeman narrator voice: he in fact, will not).
The agreements cover medicines for hemophilia, Parkinson’s, glaucoma, liver disease, and cancer. So we aren’t exactly haggling over Flintstones vitamins here.
But cheaper prescriptions weren’t the only goodies inside Big Pharma’s hostage bag. The nine companies also pledged $19.6 billion for U.S. factories, while four agreed to stock the government’s pharmaceutical bomb shelter.
UCB alone is contributing 163 tons of seizure medication. Sun Pharma and Teva are tossing in more than 120 tons of ingredients used for antibiotics, blood-pressure drugs, and other treatments.
“Why exactly does the government need 300 tons of medicine?”
- you, checking Zillow for properties with bunkers
Well, the official answer is actually pretty reasonable.
America relies heavily on foreign suppliers for many pharmaceutical ingredients. So the goal is to keep enough medicine at home that the next emergency doesn’t begin with Washington asking, “Does anybody know which container ship has the blood-pressure pills?”
At the same time, drugmakers are pouring billions into American factories, expanding direct-to-consumer sales through TrumpRx, and preparing to make less money on every prescription.
Great news for patients.
Drugmakers insist pharmacy benefit managers also deserve blame for America’s bend-over-and-cough prescription prices.
And sure, why not?
There are enough parasites feeding on the average prescription to warrant a Discovery Channel special.
But Trump can only shake down one layer at a time, and the drugmakers’ number just came up.
The White House says TrumpRx has already saved patients more than $700 million and estimates its pricing deals could save $600 billion over the next decade.
If even a slice of that comes out of U.S. drug revenue, a few premium pharmaceutical multiples may soon be transferred to hospice.
And the remaining companies, you ask?
Donnie is preparing their mandatory volunteer badges now.
At the time of publishing this article, Stocks.News holds positions in Merck and Johnson & Johnson as mentioned in the article.